Hainan Haiyao: Stock trading experiences abnormal fluctuations, progress in clinical trials of innovative drugs.

Hainan Haiyao announced that the company's stock price deviated by more than 20% for three consecutive trading days from June 22 to June 24, 2026, which is considered abnormal volatility. After verification, the company's previously disclosed information has not been corrected or supplemented, and no significant undisclosed information has been found. The company's operations are normal, and there have been no significant changes in the internal or external environment. The Phase III clinical trial of the innovative anti-liver fibrosis drug, Fufini ketone capsules, and the Phase IIb clinical trial of the innovative anti-epilepsy drug, Painga bin tablets, are progressing as planned, but there is uncertainty regarding market approval. In the first quarter of 2026, the company had a net loss of 76.4521 million yuan and owner's equity of 4.4474 million yuan.